Intimation of 33rd Annual General Meeting of the Company proposed to be held on September 28, 2026 at 03:00 P.M. through Video Conferencing/ Other Audio Visual Means.

To Date: 04/09/2026 Department of Corporate Affairs – Listing BSE Limited, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai – 400001 Scrip Code: 530313 [KIMIABL] Subject: Submission of Notice of 33rd Annual General Meeting and Annual Report for the Financial Year 2025-26. Pursuant to Regulation 34(1) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we hereby submit the Notice of the 33rd Annual General Meeting (“AGM”) along with the Annual Report of Kimia Biosciences Limited (“the Company”) for the financial year 2025-26, for your information and records. The 33rd Annual General Meeting of the Company is scheduled to be held on Monday, 28th September, 2026 at 03:00 P.M. (IST) through Video Conferencing/Other Audio-Visual Means (“VC/OAVM”), to transact the businesses as set out in the Notice convening the AGM. The Notice of the AGM along with the Annual Report for the financial year 2025-26 is being sent electronically to the Members whose e-mail addresses are registered with the Company/Depositories, in accordance with the applicable provisions of the Companies Act, 2013, the SEBI LODR Regulations and applicable circulars issued by the regulatory authorities. The aforesaid Notice and Annual Report will also be made available on the website of the Company at https://www.kimiabiosciences.com/wp- content/uploads/2026/09/Annual-report-2025-26.pdf , the website of BSE Limited and the NSDL e-Voting platform, in accordance with the applicable regulatory requirements. You are requested to kindly take the above information on your record. Thanking you, Yours faithfully, For KIMIA BIOSCIENCES LIMITED Abhishek Kumar Pandey (Company Secretary & Compliance Officer) M. No. F12457 Place: New Delhi Encl.: 33rd Annual General Meeting Notice and Annual Report for FY 2025-26. KIMIA BIOSCIENCES LIMITED egd. Office!'Works Corporate Officc willqe Bhandsi, Dadams Lake rad 974, 3" Flor, Agarwal MillenniurT Tcawer+I uuregram, Haryana-2 1U2 vetaj/ 5bhash flere, Pitarnpure. New Delhi 110034, FNDl Tel.: +3 965'16514. 9J6520U65·11 Tel.: -91 11 47063600, 470630601 compliance.kimiabiosciences@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.:L24239HR1993PLC032120 KIMIA chemistry of well being SCIENCE FORA HEALTHIER TOMORROW CORPORATE INFORMATION Board Of Directors Statutory Auditors Mr. Sameer Goel Managing Director & CEO M/s Neeraj Arora & Associates, Chartered Accountants Mr. Avinash Prabhat Independent Director (FRN: 021309N) Ms. Reema Goyal Independent & Woman S ecretarial Auditors Director M/s Maya Sharma & Associates Mr. Amulya Kumar Nayak Director New Delhi Key managerial Personnel Cost Auditors Mr. Sameer Goel M/sMahesh Singh & Co. Chief Executive Officer Cost Accountants Mr. Abhishek Kumar Pandey (FRN: 100441) Company Secretary & Compliance Officer Mr. Mani Jain Banker Chief Financial Officer Kotak Mahindra Bank Audit Committee Nomination and Remuneration Committee Mr.Avinash Prabhat Chairman Mr.Avinash Prabhat Chairman Mr. Sameer Goel Member Mr. Amulya Kumar Nayak Member Ms. Reema Goyal Member Ms. Reema Goyal Member Registrar of Transfer Agent Listed with Stock Exchange Beetal Financial & Computer Services (P) Limited BSE India Limited Beetal House, 3rd Floor, 99 Madangir, 1st Floor, Rotunda building, PJ Towers, New Delhi - 110062 Dalal Street, Mumbai - 400001 Registered Office: Corporate Office: Vill. Bhondsi, Tehsil Sohna Distt. th 974, 9 Floor, Aggarwal Millenium Tower-II, gururam – 122012, Haryana Netaji Subhash Place, Pitampura, New Delhi – 110034 E-mail: compliance.kimiabiosciences@gmail.com Biosciences Limited R&D And Growth The objective of R&D program is to research and develop new improved drugs with the goal of addressing unmet patient needs with more meticulous resources and to establish a robust portfolio for a new generation of treatments. Kimia is committed to do significant investments in drug research and development in order to produce effective, safe and affordable medicines. The team at R&D involves people with high skills and expertise having versatile Pharmaceutical exposures and are determined to make Kimia R&D as an advance Centre for Research. The Research & Development Centre, having state of Art Facility with modern & well equipped machinery is approved by Department of Scientific and Industrial Research (DSIR) vide Registration No. TU/IV- RD/4410/2021 dated 06/08/2021. A significant achievement during the year was the grant of a patent in January 2026 for Luliconazole, an antifungal drug. This milestone reflects Kimia’s growing focus on innovation and strengthens its intellectual property portfolio. R&D at Kimia has evolved much stronger and larger with increased infrastructure during the year 2025-2026 and has KF forged ahead in development of innovative technologies, cost improvements in existing products & indigenous development Apparat- us IR of key Raw materials. Autotitr- Instrum- ator )t>o Another area of advancement is induction of Intellectual Analytical property team at the R&D in addition to already existing Chemical Research development, Analytical development, UV Labratory HPLC and Regulatory and Quality assurance teams making a Instrum- complete set of teams needed to run the R&D Centre. Melting GC-HS Point Apparat- CONTENTS S. No. Particulars Page No. 1. Notice of Annual General Meeting 1-24 2. Board’s Report 25-37 3. Annexures to Board’s Report Annexure I - Related Party Transactions (Form AOC-2) 38 Annexure II - Particulars of Remuneration 39 Annexure IIA- Particulars of Employees. 40 Annexure III Declaration from CEO 41 Annexure IV – Certificate of CEO and CFO 42 Annexure V- Management Discussion and analysis report 43-46 Annexure VI-Secretarial Auditor Report 47-50 4. Independent Auditor’s Report 51-63 5. Standalone Financial Statements 64-96 6. Notes to Financial Statements 97-106 NOTICE OF THE 33rd (THIRTY-THIRD) ANNUAL GENERAL MEETING NOTICE IS HEREBY GIVEN THAT the Thirty-third (33rd) Annual General Meeting of Members of Kimia Biosciences Limited will be held on Monday, the 28th September, 2026 at 03:00 PM (IST) through video conferencing or other audio visual means (“VC/OAVM”) to transact the following business: ORDINARY BUSINESS: 1. To receive, consider and adopt the Audited Financial Statements for the year ended 31 March 2026, along with the Reports of the Directors’ and Auditors’ thereon. To consider and, if thought fit, to give your assent or dissent to the following resolution as Ordinary Resolution: “RESOLVED THAT the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026 (including the Balance Sheet as at March 31, 2026; Statement of Profit and Loss; Cash Flow Statement for the year ended March 31, 2026; Statement of changes in Equity for the year ended March 31, 2026 along with summary of significant accounting policies and the accompanying notes forming an integral part of the financial statements) along with the Report of the Board of Directors and the Statutory Auditors’ Report thereon, as placed before the meeting, be and are hereby, received, considered and adopted.” 2. To appoint a director in place of Mr. Sameer Goel (DIN: 00161786), Director, who retires by rotation, and being eligible, offers himself for re-appointment pursuant to the provisions of Section 152 of the Companies Act, 2013. To consider and, if thought fit, to give your assent or dissent to the following resolution as Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 152 and other applicable provisions, if any, of the Companies Act, 2013, Mr. Sameer Goel (DIN: 00161786) , who retires by rotation and being eligible for re-appointment, be and is hereby re-appointed as a Director of the Company.” SPECIAL BUSINESS: 3. To approve the remuneration of the Cost Auditors for the financial year ending 31st March, 2026. To cons [Showing first 8,000 characters — download PDF for full document]